Shu‐Ling Fu
-
- Andrographolide Research and Applications 11
- Pharmacology top 5%
- Immunology top 10%
- Immune Response and Inflammation 9
- Toxin Mechanisms and Immunotoxins 4
-
- Cancer-related gene regulation 5
- Pharmacology top 10%
-
- PARP inhibition in cancer therapy 6
- Cancer-related Molecular Pathways 5
-
- NF-κB Signaling Pathways 5
-
- Bioactive Compounds and Antitumor Agents 3
Shu‐Ling Fu
57 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 99
- Complementary and alternative medicine 258
- Pharmacology 112
- Immunology 230
- Molecular Biology 623
- Pharmacology 146
Countries citing papers authored by Shu‐Ling Fu
This map shows the geographic impact of Shu‐Ling Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shu‐Ling Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shu‐Ling Fu more than expected).
Fields of papers citing papers by Shu‐Ling Fu
This network shows the impact of papers produced by Shu‐Ling Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shu‐Ling Fu. The network helps show where Shu‐Ling Fu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Shu‐Ling Fu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 3 | |
| 2 | 2023 | 2 | |
| 3 | 2023 | 3 | |
| 4 | 2023 | 2 | |
| 5 | 2023 | 3 | |
| 6 | 2022 | 9 | |
| 7 | 2021 | 6 | |
| 8 | 2021 | 23 | |
| 9 | 2021 | 11 | |
| 10 | 2020 | 91 | |
| 11 | 2019 | 29 | |
| 12 | 2018 | 19 | |
| 13 | 2016 | 11 | |
| 14 | 2013 | 34 | |
| 15 | 2012 | 8 | |
| 16 | 2011 | 23 | |
| 17 | 2010 | 28 | |
| 18 | 2007 | 40 | |
| 19 | 2006 | 24 | |
| 20 | 2006 | 4 |
About Shu‐Ling Fu
Shu‐Ling Fu is a scholar working on Complementary and alternative medicine, Immunology and Toxicology, having authored 57 papers that have together received 1.3k indexed citations. Recurring topics across this work include Andrographolide Research and Applications (11 papers), Immune Response and Inflammation (9 papers), PARP inhibition in cancer therapy (6 papers), Cancer-related gene regulation (5 papers), Cancer-related Molecular Pathways (5 papers), NF-κB Signaling Pathways (5 papers), Toxin Mechanisms and Immunotoxins (4 papers) and Bioactive Compounds and Antitumor Agents (3 papers). The work is most often cited by research in Complementary and alternative medicine (258 citations), Pharmacology (112 citations) and Immunology (230 citations). Shu‐Ling Fu has collaborated with scholars based in Taiwan, United States and Canada. Frequent co-authors include Chao‐Hsiung Lin, Shih‐Kai Hung, Peter K. Vogt, Jih‐Jung Chen, Ling-Chien Hung, Cheng‐Deng Kuo, Wey‐Jinq Lin, Yi‐Ying Chiou, Ming‐Jen Cheng and Jen‐Hwey Chiu. Their work appears in journals such as Biochemical Pharmacology, Molecules, Journal of Agricultural and Food Chemistry, International Journal of Molecular Sciences and Biochemical and Biophysical Research Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.